Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism.
Adolescent
Adult
Child
Child, Preschool
Craniofacial Abnormalities
/ etiology
Female
Haploinsufficiency
Heterozygote
Humans
Infant
Intellectual Disability
/ etiology
Language Development Disorders
/ etiology
Loss of Function Mutation
Male
Pedigree
Phenotype
RNA-Binding Proteins
/ genetics
Signal Transduction
Syndrome
Young Adult
ANKRD17
Hippo pathway
Mask
Yorkie
ankyrin repeats
dysmorphism
intellectual disability
neurodevelopmental syndrome
speech delay
Journal
American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475
Informations de publication
Date de publication:
03 06 2021
03 06 2021
Historique:
received:
20
12
2020
accepted:
05
04
2021
pubmed:
29
4
2021
medline:
29
6
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
ANKRD17 is an ankyrin repeat-containing protein thought to play a role in cell cycle progression, whose ortholog in Drosophila functions in the Hippo pathway as a co-factor of Yorkie. Here, we delineate a neurodevelopmental disorder caused by de novo heterozygous ANKRD17 variants. The mutational spectrum of this cohort of 34 individuals from 32 families is highly suggestive of haploinsufficiency as the underlying mechanism of disease, with 21 truncating or essential splice site variants, 9 missense variants, 1 in-frame insertion-deletion, and 1 microdeletion (1.16 Mb). Consequently, our data indicate that loss of ANKRD17 is likely the main cause of phenotypes previously associated with large multi-gene chromosomal aberrations of the 4q13.3 region. Protein modeling suggests that most of the missense variants disrupt the stability of the ankyrin repeats through alteration of core structural residues. The major phenotypic characteristic of our cohort is a variable degree of developmental delay/intellectual disability, particularly affecting speech, while additional features include growth failure, feeding difficulties, non-specific MRI abnormalities, epilepsy and/or abnormal EEG, predisposition to recurrent infections (mostly bacterial), ophthalmological abnormalities, gait/balance disturbance, and joint hypermobility. Moreover, many individuals shared similar dysmorphic facial features. Analysis of single-cell RNA-seq data from the developing human telencephalon indicated ANKRD17 expression at multiple stages of neurogenesis, adding further evidence to the assertion that damaging ANKRD17 variants cause a neurodevelopmental disorder.
Identifiants
pubmed: 33909992
pii: S0002-9297(21)00138-5
doi: 10.1016/j.ajhg.2021.04.007
pmc: PMC8206162
pii:
doi:
Substances chimiques
ANKRD17 protein, human
0
RNA-Binding Proteins
0
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1138-1150Subventions
Organisme : NICHD NIH HHS
ID : R01 HD093570
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG009141
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG009599
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Informations de copyright
Copyright © 2021 American Society of Human Genetics. All rights reserved.
Références
Curr Opin Cell Biol. 2017 Dec;49:99-107
pubmed: 29316535
Am J Hum Genet. 2011 Aug 12;89(2):289-94
pubmed: 21782149
Hum Genet. 2017 Nov;136(11-12):1419-1429
pubmed: 28940097
J Biol Chem. 2009 Mar 20;284(12):7875-88
pubmed: 19150984
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
iScience. 2019 Jul 26;17:101-118
pubmed: 31255983
J Biol Chem. 2018 Jun 22;293(25):9570-9579
pubmed: 29695508
PeerJ. 2014 Feb 06;2:e264
pubmed: 24688847
Development. 2002 Jan;129(1):71-82
pubmed: 11782402
Front Mol Neurosci. 2018 Jan 12;10:445
pubmed: 29379413
Am J Med Genet A. 2015 Dec;167A(12):3113-20
pubmed: 26284580
Science. 2017 Dec 8;358(6368):1318-1323
pubmed: 29217575
Elife. 2019 Oct 29;8:
pubmed: 31661072
J Cell Sci. 2018 Jul 6;131(13):
pubmed: 29848658
Nat Genet. 2019 Jan;51(1):88-95
pubmed: 30531870
FEBS Lett. 2009 Sep 3;583(17):2765-71
pubmed: 19619540
J Mol Biol. 2010 May 28;399(1):168-81
pubmed: 20398677
Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
Eur J Immunol. 2012 May;42(5):1304-15
pubmed: 22328336
Curr Biol. 2013 Feb 4;23(3):223-8
pubmed: 23333315
FEBS Lett. 2013 Jul 11;587(14):2137-42
pubmed: 23711367
BMC Med Genomics. 2020 Apr 16;13(1):63
pubmed: 32299451
J Biol Chem. 2003 Dec 26;278(52):52290-7
pubmed: 14557257
Nature. 2014 Nov 13;515(7526):209-15
pubmed: 25363760
Nature. 2014 Nov 13;515(7526):216-21
pubmed: 25363768
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Nat Genet. 2015 Jun;47(6):582-8
pubmed: 25961944
Am J Hum Genet. 2011 Jan 7;88(1):115-20
pubmed: 21211618
Curr Biol. 2013 Feb 4;23(3):229-35
pubmed: 23333314
Protein Sci. 2004 Jun;13(6):1435-48
pubmed: 15152081
Biochemistry. 2006 Dec 26;45(51):15168-78
pubmed: 17176038
Nat Genet. 2007 Jan;39(1):25-7
pubmed: 17173049